Leman Biotech

Leman Biotech is excited to announce the successful treatment of the first pediatric patient enrolled in its IIT clinical trial of Meta10-19 infusion. The patient, treated with an extremely low dose, achieved complete remission and was discharged without complications. Notably, the dose is only 1% of the conventional CD19 CAR-T dose, significantly reducing the risk of severe side effects such as cytokine release syndrome. The low dose offers great potential to shorten production time and enable rapid manufacturing using small automated equipment, thereby lowering production costs and enhancing the therapy's accessibility. Leman Biotech will continue the efforts to commercialize our innovative metabolic immunotherapy against cancer to benefit more patients. Please stay tuned to our website www.lemanbio.com/en for more updates of Leman Biotech. #biotech #immunotherapy #cartcelltherapy #cellandgenetherapy #clinicaltrials #oncology #cancertreatment

Leman Biotech is pleased to announce the completion of new financing totaling USD 7 million in Angel+ and Angel++ rounds！ Many thanks to the recognition and support from new and existing investors. It is this support that turns the 'idea' of the laboratory into a 'cure' to tackle diseases and save patients. Special thanks to our patients and their families for their trust and support, which has greatly strengthened our confidence in developing innovative cancer drugs! This financing will help us accelerate the advancement of our core pipeline to clinical translation, speed up development of new technologies, and further expand the application scope of the Meta 10 technology platform, so that safe, effective, and accessible metabolic reprogramming drugs can benefit the majority of cancer patients earlier! #biotech #financing #carttherapy #cellandgenetherapy #celltherapy #cancertherapy #hematologies #cancertreatment #immunotherapy #cancerimmunotherapy

Leman Biotech is pleased to announce an oral presentation of its IIT clinical trials to be delivered at EHA 2024 in Madrid, Spain! This time, a member from the PI team of clinical trials will present the updated clinical data on Meta 10-19 CAR-T cell therapy for relapsed or refractory B cell hematological malignancies. The oral presentation (11:45 am to 12:00 am, June 16) will be part of the "gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research" session. Welcome to join the presentation ! #cart #carttherapy #cellandgenetherapy #celltherapy #immunotherapy #hematologies #EHA #EHA2024

Leman Biotech is pleased to announce its oral presentation to be delivered at ASGCT 2024 in Baltimore! This time, Leman Biotech will present its updated clinical data (cut-off March 18, 2024 ) and share more cases of the IIT clinical trials on Meta 10-19 CAR-T cell therapy for relapsed or refractory CD19+ B cell hematological malignancies. The oral presentation (9:15 am to 9:30 am) will be part of the Late-Breaking Abstracts II scheduled at 8:00 am to 9:45 am in Ballroom 4. Welcome to join us then! #cart #carttherapy #cellandgenetherapy #celltherapy #cancertherapy #hematologies #ASGCT #ASGCT2024

Leman Biotech has extended its love and care to children. Leman Biotech is excited to announce that its IIT clinical trials of Metabolically Armed CD19 CAR-T cell therapy to pediatric patients with relapsed or refractory B-cell hematological malignancies has been launched in Zhejiang University Children's Hospital! Leman Biotech will continue the efforts to commercialize our innovative metabolic immunotherapy against cancer to benefit more patients. Please stay tuned for more updates of Leman Biotech. #biotech #immunotherapy #cartcelltherapy #clinicaltrials #cellandgenetherapy #oncology #cancertreatment #hematologicalmalignancies #hematology

Join us at Swiss Biotech Association Day 2024 in Basel, Switzerland! We're thrilled to announce that Dr. Karthik Sathiyanadan, our Director of Translational Research at Leman Biotech Swiss Research Center, will be taking the stage at the Swiss Biotech Day. Karthik will be presenting in the session "Emerging Biotech Company Presentations," offering insights into our groundbreaking Meta-10 technology. 📍 Event: Swiss Biotech Day 2024 📅 Date: April 22nd-23rd, 2024 🏛 Venue: Basel, Switzerland Don't miss this opportunity to connect with Leman biotech and learn about cutting edge AI Enabled Metabolic Immunotherapy to Cure Cancers. #SwissBiotechDay #BiotechInnovation #Biopole #Basel2024

Leman Biotech will present the results of the IIT clinical trials on investigating Meta 10-19 CAR-T cell therapy for relapsed or refractory CD19+ B cell hematological malignancies at AACR 2024. The oral presentation (3:50 pm to 4:05 pm) will be part of the Minisymposium Late-Breaking Research Session scheduled at 2:30 pm to 4:30 pm, April 8, 2024. You are welcome to join us then! #AACR #AACR2024 #Cellandgenetherapy #clinicaltrials #celltherapy #CART #CARTtherapy #leukemia #lymphoma #hematology #hematologicalmalignancies #immunometabolism

Leman Biotech will present the results of the IIT clinical trials on investigating Meta 10-19 CAR-T cell therapy for relapsed or refractory CD19+ B cell hematological malignancies at AACR 2024. The oral presentation (3:50 pm to 4:05 pm) will be part of the Minisymposium Late-Breaking Research Session scheduled at 2:30 pm to 4:30 pm, April 8, 2024. You are welcome to join us then! #AACR #AACR2024 #Cellandgenetherapy #clinicaltrials #celltherapy #CART #CARTtherapy #leukemia #lymphoma #hematology #hematologicalmalignancies #immunometabolism

Leman Biotech is pleased to announce that our IIT clinical studies of Metabolically Enhanced CD19 CAR-T has been selected for oral presentation at the Late-Breaking Minisymposium of the American Association for Cancer Research (AACR) Annual Meeting 2024, San Diego, with session information as the following:   Session Title: Minisymposium: Late-Breaking Research Session Date/Time: Monday, April 8; 2:30-4:30 PM   The AACR Annual Meeting 2024, scheduled to take place on April 5-10 in San Diego, California, is the focal point of the cancer research community where scientists, clinicians, other health care professionals, etc., gather to share the latest advances in cancer science and medicine. The work of the best minds in cancer research all over the world will be highlighted in the meeting. Leman Biotech is proud to be one of them. We are looking forward to meeting colleagues of the international cancer community and showcasing our innovative Metabolically Enhanced CD19 CAR-T cell therapies in AACR Annual Meeting 2024!

Leman Biotech is pleased to announce that our IIT clinical studies of Metabolically Enhanced CD19 CAR-T has been selected for oral presentation at the Late-Breaking Minisymposium of the American Association for Cancer Research (AACR) Annual Meeting 2024, San Diego, with session information as the following:   Session Title: Minisymposium: Late-Breaking Research Session Date/Time: Monday, April 8; 2:30-4:30 PM   The AACR Annual Meeting 2024, scheduled to take place on April 5-10 in San Diego, California, is the focal point of the cancer research community where scientists, clinicians, other health care professionals, etc., gather to share the latest advances in cancer science and medicine. The work of the best minds in cancer research all over the world will be highlighted in the meeting. Leman Biotech is proud to be one of them. We are looking forward to meeting colleagues of the international cancer community and showcasing our innovative Metabolically Enhanced CD19 CAR-T cell therapies in AACR Annual Meeting 2024!